Gold Or Platinum Patents (Class 424/649)
  • Patent number: 11406598
    Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: August 9, 2022
    Assignee: NIVAGEN PHARMACEUTICALS, INC.
    Inventors: Bala Tripura Sundari Chodavarapu, Thirupathi Mangali, Jay Shukla, Anand Shukla, Dasaradhi Lakkaraju
  • Patent number: 11400266
    Abstract: A two-part bioactive agent delivery system, the system including a disposable part comprising an agent reservoir, a bolus chamber, the volume of the bolus chamber being less than the volume of the agent reservoir, an agent outlet, and a valve having a first position communicating the agent reservoir with the bolus chamber and a second position communicating the bolus chamber with the outlet; and a reusable part including a valve driver, a power source and control electronics, the control electronics being adapted to control the valve driver to actuate the valve to deliver bioactive agent from the agent reservoir to the agent outlet; the system further having a spring extending between the agent reservoir piston and a surface of the reusable part or of the disposable part to pressurize the agent reservoir when the spring is compressed and the agent reservoir contains a quantity of bioactive agent.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: August 2, 2022
    Assignee: Morningside Venture Investments Limited
    Inventors: Zita S. Netzel, Gary Stacey, Alexander David Norman, Congyi Huang, Timothy Charles Frearson, Charles Frazer Kilby, Patrick H. Ruane, Alan J. Levy, Kevin W. Gelston, Jennifer Darmour, Jenny E. Hapgood, David Evans Roth, Ronald A. Overbeck, Ling-Kang Tong
  • Patent number: 11357753
    Abstract: Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 14, 2022
    Assignee: Acacia Pharma Ltd
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Gabriel Fox
  • Patent number: 11304938
    Abstract: The present invention features methods for increasing sensitivity and/or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and/or reversing resistance to chemotherapy.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 19, 2022
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Josephine Kahn, Siddhartha Jaiswal, Benjamin Ebert
  • Patent number: 11304943
    Abstract: The invention is based on the finding that co-administration of 6-?-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-?-naltrexol with vitamin D results in a greater decrease in the growth of cancer cells compared to the sum of the effects of each agent when administered in isolation.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 19, 2022
    Assignee: LDN PHARMA LIMITED
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11246822
    Abstract: A method for skin care and/or maintenance including applying or administering a preparation to a subject is provided. The preparation includes a biomedical composition, and the biomedical composition includes an effective amount of micelle, wherein the micelle includes a hyaluronic acid and/or a derivative thereof and a modified histidine. The modified histidine is grafted to at least one primary hydroxyl group of the hyaluronic acid and/or the derivative thereof, and a graft ratio of the modified histidine is 1-100%. Moreover, the hyaluronic acid and/or the derivative thereof and the modified histidine form the micelle on a weight percentage of 0.2-300:1.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: February 15, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ting-Yu Shih, Lu-Chih Wang, Yuan-Kun Yu, Yi-Ting Hsieh, Yu-Chun Liu, Jing-Wen Tang
  • Patent number: 11229665
    Abstract: The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: January 25, 2022
    Assignee: HOLY STONE HEALTHCARE CO., LTD.
    Inventor: Hua-Yang Lin
  • Patent number: 11208697
    Abstract: The present invention relates to methods, systems and kits for the diagnosis, prognosis, and treatment of bladder cancer in a subject. The invention also provides biomarkers that define subgroups of bladder cancer, clinically useful classifiers for distinguishing bladder cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping bladder cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping bladder cancer in a subject. Classifiers for subtyping a bladder cancer are provided. Methods of treating bladder cancer based on molecular subtyping are also provided.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 28, 2021
    Assignees: Decipher Biosciences, Inc., The University of British Columbia
    Inventors: Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black
  • Patent number: 11202765
    Abstract: A novel pharmaceutical composition is provided comprising beta-caryophyllene or a functionally equivalent derivative, analogue or pharmaceutically acceptable salt thereof in a base cream comprising triglycerides, phospholipid, water, wax, alcohol, with other minor constituents. The composition is useful to treat pain and/or inflammation, reduce fine lines and wrinkles, moisturize, and protect skin with anti-bacterial, anti-fungal and insect repelling properties.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: December 21, 2021
    Inventor: John Enrique Mata
  • Patent number: 11179394
    Abstract: The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient. The compounds utilized in this invention are represented by formula I and formula II: wherein the variables are as defined herein.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 23, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Thomas Helleday, Kumar Sanjiv
  • Patent number: 11166908
    Abstract: The invention relates to pharmacology and to a composition for making an antitumor agent in the form of a solution for injection. The composition contains alloferon at a concentration of 0.05 to 0.1% wt, cis-diamminedichloridoplatinum at a concentration of 0.01 to 0.05% wt, and water. The composition of the present invention features antitumor activity and hypotoxicity. 1 Figure, 3 Tables, 5 examples.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: November 9, 2021
    Inventor: German Petrovich Bekker
  • Patent number: 11160758
    Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 2, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
  • Patent number: 11123353
    Abstract: The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 21, 2021
    Assignee: Zhejiang Chinese Medical University
    Inventors: Shengwu Huang, Ting Huang, Meijia Wu
  • Patent number: 11110108
    Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Diane M. Boucher, Shawn M. Hillier, Wanjung Tsai, Brian Hare, William Markland, David A. Newsome, Marina S. Penney
  • Patent number: 11110303
    Abstract: Embodiments disclosed herein provide methods for treating neoplasm in a mammal, comprising intratumorally administering to the neoplasm an effective amount of a pharmaceutical composition comprising: a hapten; and a redox agent, whereby the neoplasm is treated.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 7, 2021
    Inventor: Baofa Yu
  • Patent number: 11097130
    Abstract: Systems and methods for targeting specific cell types by selective application of ultrasonic harmonic excitation at their resonance frequency (“oncotripsy”) are presented. The systems and methods result in the lysis of targeted cell types by using ultrasonic harmonic excitations that have been specifically tuned to disrupt the nuclear membrane of the targeted cells types by inducing a destructive vibrational response therein while leaving non-targeted cell types intact. The target cells types may be cancerous cells.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 24, 2021
    Assignee: California Institute of Technology
    Inventors: Michael Ortiz, Stefanie Heyden
  • Patent number: 11098033
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 24, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: John J Turchi, Navnath Gavande, Pamela S. Vandervere-Carozza
  • Patent number: 11058746
    Abstract: The present invention provides a method of preventing or treating fibrosis in a subject, comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma lucidum, Ganoderma lucidum, Ganoderma tsugae, Ganoderma microsporum or Ganoderma sinensis to the subject, thereby preventing or treating a fibrosis.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 13, 2021
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Cheng-Chia Yu
  • Patent number: 11040052
    Abstract: The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 22, 2021
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Guido Kroemer, Guillermo Marino, Federico Pietrocola
  • Patent number: 10980774
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: April 20, 2021
    Assignees: MEI PHARMA, INC., THE SPANISH NATIONAL CANCER RESEARCH CENTRE
    Inventors: Daniel P. Gold, Miguel Quintela-Fandino
  • Patent number: 10940215
    Abstract: The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 9, 2021
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Yong-Hee Kim, Hyung Jin Kim, Jee Young Chung, Yoon Sung Song
  • Patent number: 10898473
    Abstract: This application describes compounds, compositions, and combinations thereof that can be used to treat cancer, such as cancers with and without BRAF and/or KRAS mutations.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 26, 2021
    Assignee: EVOL SCIENCE LLC
    Inventors: Andrew J. Andrews, Vikram Bhattacharjee
  • Patent number: 10869879
    Abstract: This application describes compounds, compositions, and combinations thereof that can be used to treat cancer, such as cancers with and without BRAF and/or RAS mutations.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 22, 2020
    Assignee: EVOL SCIENCE LLC
    Inventor: Vikram Bhattacharjee
  • Patent number: 10857113
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10821095
    Abstract: IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignee: Bold Therapeutics, Inc.
    Inventors: Suzanne Bakewell, Jyothi Sethuraman
  • Patent number: 10821114
    Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 3, 2020
    Assignees: INSTITUT CURIE, HARMONIC PHARMA
    Inventors: Arnaud Sinan Karaboga, Violeta Isabel Perez-Nueno, Michel Souchet, Didier Decaudin
  • Patent number: 10772898
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 15, 2020
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10751296
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 25, 2020
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 10744171
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Duke University
    Inventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
  • Patent number: 10632115
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Yu
  • Patent number: 10612093
    Abstract: The present invention relates to a method of selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising sequences capable of directing the cleavage of a target nucleic acid molecule to release a fragment comprising the ROI and sequences capable of templating the circularisation and ligation of the target fragment. The circularised molecule thus obtained contains the selected ROI and may be subjected to further analysis and/or amplification etc. Also provided are probes and kits for use in such methods.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 7, 2020
    Assignee: NAVINCI DIAGNOSTICS AB
    Inventors: Ulf Landegren, Rachel Yuan Nong
  • Patent number: 10595550
    Abstract: The present invention is directed to a therapeutic composition including an active therapeutic ingredient combined with a liquid or solution based carbonated beverage. The invention as described details the use or administration of the therapeutic composition so as to treat a variety of ailments. The present invention is also directed to a method of administering the therapeutic composition to an individual for the purposes of alleviating an ailment. In a further arrangement, the therapeutic composition is provided to a user as a pre-packaged volume containing a single effective dose of the therapeutic agent.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: March 24, 2020
    Assignee: VISION PHARMA, LLC
    Inventor: Sander S Busman
  • Patent number: 10576082
    Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.
    Type: Grant
    Filed: September 3, 2017
    Date of Patent: March 3, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Yung-Feng Liao, Bo-Jeng Wang
  • Patent number: 10485768
    Abstract: The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 26, 2019
    Assignee: Signpath Pharma, Inc.
    Inventors: Laura A. Sordillo, Peter P. Sordillo, Lawrence Helson
  • Patent number: 10386359
    Abstract: Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS), INSTITUT DE CANCERLOGIE DE L'OUEST—SITE RENE GAUDUCHEAU
    Inventors: Francois Paris, Nolwenn Dubois, Emmanuel Rio, Natacha Ripoche
  • Patent number: 10300026
    Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 28, 2019
    Assignees: Shanxi Yabao Health Products Co., Ltd., Yabao Pharmaceutical Group Co., Ltd.
    Inventors: Jianguo Zhang, Wuxian Ren, Peng Wang, Bangqin Ya
  • Patent number: 10280178
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 7, 2019
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10265294
    Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 23, 2019
    Assignee: Yale University
    Inventors: Gil G. Mor, Ayesha Alvero
  • Patent number: 10251842
    Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: April 9, 2019
    Assignee: King Abdulaziz University
    Inventors: Amna Ali Nasser Saddiq, Shaker Ahmad Mousa, Deena Shaker Mousa
  • Patent number: 10213449
    Abstract: Provided are methods and compositions for treating an individual who has a medulloblastoma. Methods for treating an individual who has a medulloblastoma tumor can include a step of administering to the individual, at a dose sufficient to reduce the size and/or growth rate of the medulloblastoma tumor, a composition that includes a casein kinase II (CK2) inhibitor (e.g., a CK2-selective inhibitor such as CX-4945). In some cases, the medulloblastoma tumor is a hedgehog-dependent medulloblastoma tumor. In some cases, the medulloblastoma tumor is a hedgehog-independent medulloblastoma tumor. In some cases, the medulloblastoma tumor is smoothened inhibitor-resistant (SMO inhibitor-resistant). In some cases, the medulloblastoma is resistant to treatment with 4,5,6,7-tetrabromo-2H-benzotriazole (TBB). In some cases, the dose is sufficient to cause long term regression of the medulloblastoma tumor, and in some cases, the dose is sufficient to increase the chance of survival of the individual.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Teresa Purzner, Matthew Peter Scott
  • Patent number: 10155006
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 18, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10145824
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with refractive index (RI) detection; the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: December 4, 2018
    Assignee: Del Mar Pharmaceuticals (BC) Ltd.
    Inventor: Xiaoyun Liu
  • Patent number: 10072021
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 11, 2018
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10066003
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10052304
    Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form H2O2, and one or more anti-cancer therapies.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 21, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Bryan G. Allen, Douglas R. Spitz, Garry R. Buettner, Joseph Cullen, Joshua Schoenfeld, Michael Schultz, Fenghuang Zhan
  • Patent number: 9994843
    Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: June 12, 2018
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
  • Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • Patent number: 9950025
    Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of muramyl dipeptide, and their use in the treatment of neoplastic disease.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 24, 2018
    Assignee: Innate Immunotherapeutics Limited
    Inventors: Frank B. Gelder, Gillian Alison Webster
  • Patent number: 9895366
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: February 20, 2018
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Xu
  • Patent number: 9884086
    Abstract: Disclosed is a method for providing information used for comparing restoration rates of damaged DNA, wherein information about a time period when Ataxia telangiectasia and Rad3 related (‘ATR’) activation is accelerated, on the basis of alternative information about an expression level of cryptochrome may be acquired, therefore, it can be determined that a restoration rate of damaged DNA is high at a time period when the expression level of cryptochrome is high. Accordingly, a time period when a restoration rate of DNA damaged by different causes is high, can be determined. Further, it is possible to estimate a time period when side effects occurring due to using an anticancer drug are minimized, and then, utilize the estimated result in determining the timing of administration of an anticancer drug.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 6, 2018
    Assignee: DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY—ACADEMY COOPERATION
    Inventors: Tae Hong Kang, Jeong Min Park, Ji Ye Choi, Sun Hee Leem